Recurrent Respiratory Papillomatosis
Conditions
Interventions
Test group:Bevacizumab injection, 100 mg vs. 4 ml, was administered intravenously with a dose of 5-10 mg/kg. After intravenous infusion, the changes of blood pressure and heart rate of patients were m
Sponsors
The Affiliated BenQ Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Ages 1-75; 2) The lesion invaded the lower respiratory tract; 3) Wide range of lesions with Derkay score >= 15; 4) Recurrences >= 3 times in 12 months before treatment; 5) Complete case data and clear records; 6) Histopathology confirmed recurrent respiratory papilloma.
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) Bevacizumab allergy; 3) Receive other auxiliary programs or open surgery with major trauma within 3 months; 4) Have other throat diseases that affect treatment or follow-up; 5) Severe cardiac, liver and renal insufficiency or other surgical contraindications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean relapse-free survival during follow-up;Safety of Bevacizumab therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean standardized volume reduction rate during treatment; Derkay score at mean recurrence during follow-up;The voice disturbance scale 10 was evaluated before treatment and during follow-up; | — |
Countries
China
Contacts
Public ContactYuanyuan Lu
The Affiliated BenQ Hospital of Nanjing Medical University
Outcome results
None listed